Among the 123 patients with Parkinson disease–associated genetic mutations, 80 (65.0%) (27 LRRK2, 30 GBA, 12 homozygous PRKN, and 11 heterozygous PRKN) were included in the meta-analysis for therapy end points, and 7 single cases (5.7%) underwent intraindividual patient analyses (Tables 1 and 3). Here, PRKN is linked to Parkinson disease.